251 related articles for article (PubMed ID: 27486763)
1. Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin.
Pass HI; Lavilla C; Canino C; Goparaju C; Preiss J; Noreen S; Blandino G; Cioce M
Oncotarget; 2016 Aug; 7(35):56408-56421. PubMed ID: 27486763
[TBL] [Abstract][Full Text] [Related]
2. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.
Quail DF; Bowman RL; Akkari L; Quick ML; Schuhmacher AJ; Huse JT; Holland EC; Sutton JC; Joyce JA
Science; 2016 May; 352(6288):aad3018. PubMed ID: 27199435
[TBL] [Abstract][Full Text] [Related]
3. Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes.
Webb MW; Sun J; Sheard MA; Liu WY; Wu HW; Jackson JR; Malvar J; Sposto R; Daniel D; Seeger RC
Int J Cancer; 2018 Sep; 143(6):1483-1493. PubMed ID: 29665011
[TBL] [Abstract][Full Text] [Related]
4. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
Manthey CL; Johnson DL; Illig CR; Tuman RW; Zhou Z; Baker JF; Chaikin MA; Donatelli RR; Franks CF; Zeng L; Crysler C; Chen Y; Yurkow EJ; Boczon L; Meegalla SK; Wilson KJ; Wall MJ; Chen J; Ballentine SK; Ott H; Baumann C; Lawrence D; Tomczuk BE; Molloy CJ
Mol Cancer Ther; 2009 Nov; 8(11):3151-61. PubMed ID: 19887542
[TBL] [Abstract][Full Text] [Related]
5. Colony-stimulating factor-1 receptor provides a growth advantage in epithelial cancer cell line A431 in the presence of epidermal growth factor receptor inhibitor gefitinib.
Niehus SE; Tran DDH; Mischak M; Koch A
Cell Signal; 2018 Nov; 51():191-198. PubMed ID: 30075184
[TBL] [Abstract][Full Text] [Related]
6. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
7. Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy.
Nishikawa S; Konno M; Hamabe A; Hasegawa S; Kano Y; Ohta K; Fukusumi T; Sakai D; Kudo T; Haraguchi N; Satoh T; Takiguchi S; Mori M; Doki Y; Ishii H
Int J Oncol; 2013 Apr; 42(4):1437-42. PubMed ID: 23440340
[TBL] [Abstract][Full Text] [Related]
8. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
Mok S; Tsoi J; Koya RC; Hu-Lieskovan S; West BL; Bollag G; Graeber TG; Ribas A
BMC Cancer; 2015 May; 15():356. PubMed ID: 25939769
[TBL] [Abstract][Full Text] [Related]
10. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts.
Paulus P; Stanley ER; Schäfer R; Abraham D; Aharinejad S
Cancer Res; 2006 Apr; 66(8):4349-56. PubMed ID: 16618760
[TBL] [Abstract][Full Text] [Related]
11. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
12. The CSF-1-receptor inhibitor, JNJ-40346527 (PRV-6527), reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis.
Manthey CL; Moore BA; Chen Y; Loza MJ; Yao X; Liu H; Belkowski SM; Raymond-Parks H; Dunford PJ; Leon F; Towne JE; Plevy SE
PLoS One; 2019; 14(11):e0223918. PubMed ID: 31710624
[TBL] [Abstract][Full Text] [Related]
13. CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer.
Kai K; Iwamoto T; Zhang D; Shen L; Takahashi Y; Rao A; Thompson A; Sen S; Ueno NT
Sci Rep; 2018 Jun; 8(1):9427. PubMed ID: 29930294
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
Togashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K
J Thorac Oncol; 2015 Jan; 10(1):93-101. PubMed ID: 25384171
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model.
Zhang H; Almuqbil RM; Alhudaithi SS; Sunbul FS; da Rocha SRP
Int J Pharm; 2021 Apr; 598():120350. PubMed ID: 33545279
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
17. Effects of GM-CSF and M-CSF on tumor progression of lung cancer: roles of MEK1/ERK and AKT/PKB pathways.
Uemura Y; Kobayashi M; Nakata H; Kubota T; Bandobashi K; Saito T; Taguchi H
Int J Mol Med; 2006 Aug; 18(2):365-73. PubMed ID: 16820947
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin.
Yu R; Jin H; Jin C; Huang X; Lin J; Teng Y
Cell Biochem Funct; 2018 Mar; 36(2):80-87. PubMed ID: 29372560
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src.
Diao Y; Ma X; Min W; Lin S; Kang H; Dai Z; Wang X; Zhao Y
Cancer Lett; 2016 Aug; 379(1):12-23. PubMed ID: 27195913
[TBL] [Abstract][Full Text] [Related]
20. The c.1085A>G Genetic Variant of
Yeh YM; Hsu SJ; Lin PC; Hsu KF; Wu PY; Su WC; Chang JY; Shen MR
Clin Cancer Res; 2017 Oct; 23(20):6021-6030. PubMed ID: 28724665
[No Abstract] [Full Text] [Related]
[Next] [New Search]
